Sal Test Code | Name | Alternate Names | Search | |
---|---|---|---|---|
9121 | ( B ) Right Lateral Mid Site (Rlm)- Diagnosis | https://www.shermanabrams.com/?p=91417 | RLM-D | 9121 ( B ) Right Lateral Mid Site (Rlm)- Diagnosis RLM-D |
9103 | ( C ) Right Lateral Base Site (Rlb)- Grossing | https://www.shermanabrams.com/?p=91418 | RLB-G | 9103 ( C ) Right Lateral Base Site (Rlb)- Grossing RLB-G |
9132 | ( H ) Left Lateral Mid Site (Llm)- Diagnosis | https://www.shermanabrams.com/?p=91419 | LLM-D | 9132 ( H ) Left Lateral Mid Site (Llm)- Diagnosis LLM-D |
8943 | 14.3.3 ETA, Rheum. Arthritis | https://www.shermanabrams.com/?p=91422 | 14.3.3n Protein ETA | 8943 14.3.3 ETA, Rheum. Arthritis 14.3.3n Protein ETA |
3429 | 17-Ketosteroids, 24 Hour Urine | https://www.shermanabrams.com/?p=91424 | 17 KETO | 3429 17-Ketosteroids, 24 Hour Urine 17 KETO |
7637 | 21-Hydroxylase Antibodies | https://www.shermanabrams.com/?p=91425 | 21_hydroxylase_LC | 7637 21-Hydroxylase Antibodies 21_hydroxylase_LC |
90530 | 2-Hydroxymidazolam | https://www.shermanabrams.com/?p=91426 | Udt 2 Hyd | 90530 2-Hydroxymidazolam Udt 2 Hyd |
90249 | 30039 - ALPHA-1,3-GALACTOSE IgE | https://www.shermanabrams.com/?p=91427 | ALPHA_GAL IgE_SR | 90249 30039 - ALPHA-1,3-GALACTOSE IgE ALPHA_GAL IgE_SR |
9871 | 5' Nucleotidase | https://www.shermanabrams.com/?p=91428 | 5' Nucleotidase_LC | 9871 5' Nucleotidase 5' Nucleotidase_LC |
2793 | 5-Hydroxyindoleacetic Acid (HIAA), Quantitative, 24-Hr Urine | https://www.shermanabrams.com/?p=91429 | 5HIAA_24Hr_Ur | 2793 5-Hydroxyindoleacetic Acid (HIAA), Quantitative, 24-Hr Urine 5HIAA_24Hr_Ur |
1730 | 5-Hydroxyindoleacetic Acid, 24 Hr Urine | https://www.shermanabrams.com/?p=91430 | Serotonin_24 hr_U | 1730 5-Hydroxyindoleacetic Acid, 24 Hr Urine Serotonin_24 hr_U |
90661 | 6-Acetylmorphine | https://www.shermanabrams.com/?p=91431 | 6-Actlm_Scrn | 90661 6-Acetylmorphine 6-Actlm_Scrn |
2558 | 6MAM (Heroin Metabolite) LC-MS/MS | https://www.shermanabrams.com/?p=91432 | rdx6MAM_S | 2558 6MAM (Heroin Metabolite) LC-MS/MS rdx6MAM_S |
2672 | 6MAM (Heroin Metabolite) LC-MS/MS | https://www.shermanabrams.com/?p=91433 | rdx6MAM_U | 2672 6MAM (Heroin Metabolite) LC-MS/MS rdx6MAM_U |
90535 | 6mam (Heroin Metabolites) | https://www.shermanabrams.com/?p=91434 | Udt 6 Mam | 90535 6mam (Heroin Metabolites) Udt 6 Mam |
90684 | 6-MAM (Heroin) | https://www.shermanabrams.com/?p=91435 | 6-MAM_U | 90684 6-MAM (Heroin) 6-MAM_U |
91684 | 6-MAM (Heroin) | https://www.shermanabrams.com/?p=91436 | 6-MAM_S | 91684 6-MAM (Heroin) 6-MAM_S |
90708 | 7-AminoClonazepam | https://www.shermanabrams.com/?p=91437 | 7-Amino_U | 90708 7-AminoClonazepam 7-Amino_U |
91708 | 7-AminoClonazepam | https://www.shermanabrams.com/?p=91438 | 7-Amino_S | 91708 7-AminoClonazepam 7-Amino_S |
90528 | 7-Aminoclonazepam | https://www.shermanabrams.com/?p=91439 | Udt 7 Amin | 90528 7-Aminoclonazepam Udt 7 Amin |
90759 | 7-Hydroxymitragynine | https://www.shermanabrams.com/?p=91440 | 7-Hdrxymt_U | 90759 7-Hydroxymitragynine 7-Hdrxymt_U |
120 | ABO Grouping and Rho(D) Typing | https://www.shermanabrams.com/?p=91443 | ABO_RH_LC | 120 ABO Grouping and Rho(D) Typing ABO_RH_LC |
122 | ABO Grouping and Rho(D) Typing | https://www.shermanabrams.com/?p=91444 | ABO_RH_LC | 122 ABO Grouping and Rho(D) Typing ABO_RH_LC |
125 | ABO Grouping and Rho(D) Typing | https://www.shermanabrams.com/?p=91445 | ABO_RH_LC | 125 ABO Grouping and Rho(D) Typing ABO_RH_LC |
405 | ABO Grouping and Rho(D) Typing | https://www.shermanabrams.com/?p=91446 | ABO_RH_LC | 405 ABO Grouping and Rho(D) Typing ABO_RH_LC |
Gastrointestinal Pathogen Panel
Alternate Name: GastroPathoPanel(GPP)
| GPP
SAL Code:
2200
CPT:
87507
Loinc:
82195-9
Turn Around Time:
1 Day
Setup:
Daily
Department:
Gastrointestinal Pathogen Panel
Performing Laboratory:
Sherman Abrams Laboratory
Methodology:
Polymerase Chain Reaction (PCR)
Specimen Requirements:
Primary Tube:
Cary Blair
Primary Substance:
Stool
Alternate Sample Info:
Fecal Swab
Temperature
Period
Stable Ambient:
4 Days
Stable Fridge:
4 Days
Rejection Criteria:
Improper labeling, expired collection devices, leaking containers, obvious PCR inhibitors, samples that fail internal controls for having sufficient DNA material, improper collection or shipment or storage of sample, any collection devices besides the approved transport media listed above.
Clinical Info:
The BioFire GI Panel is a multiplexed nucleic acid test intended for the simultaneous qualitative detection and identification of nucleic acids from multiple bacteria, viruses, and parasites directly from stool samples in Cary Blair transport medium obtained from individuals with signs and/or symptoms of gastrointestinal infection.
The following bacteria (including several diarrheagenic E.coli/Shigella pathotypes), parasites, and viruses are identified using the BioFire GI Panel:
• Campylobacter (C. jejuni/C. coli/C. upsaliensis)
• Clostridium difficile (C. difficile) toxin A/B
• Plesiomonas shigelloides
• Salmonella
• Vibrio (V. parahaemolyticus/V. vulnificus/V. cholerae), including specific identification of
Vibrio cholerae
• Yersinia enterocolitica
• Enteroaggregative Escherichia coli (EAEC)
• Enteropathogenic Escherichia coli (EPEC)
• Enterotoxigenic Escherichia coli (ETEC) lt/st
• Shiga-like toxin-producing Escherichia coli (STEC) stx1/stx2 (including specific
identification of the E. coli O157 serogroup within STEC)
• Shigella/Enteroinvasive Escherichia coli (EIEC)
• Cryptosporidium
• Cyclospora cayetanensis
• Entamoeba histolytica
• Giardia lamblia (also known as G. intestinalis and G. duodenalis)
• Adenovirus F 40/41
• Astrovirus
• Norovirus GI/GII
• Rotavirus A
• Sapovirus (Genogroups I, II, IV, and V)
Sample Collection:
Stool should be collected in a clean and dry container and transported to a Cary Blair transport media according to standard technique. Care should be taken that no antimicrobials or disinfectants such as bleach come in contact with the specimen. When using the FecalSwab transport media please use the following steps to ensure proper transport:
1) Open the peel pouch and remove the swab. DO NOT touch the tip of the swab, always hold the swab on the bottom end away from the tip.
2) Collect stool into a clean and dry container. Holding the FecalSwab by the bottom of the swab, insert the flocked tip fully into the stool and fully coat the swab tip. NOTE: Bloody, slimy, or watery areas of stool should be selected and sampled.
3) Transfer the swab into the FecalSwab tube and check that the maximum filling line (“MAX FILL) on the label is not exceeded.
4) Hold the tube away from your face. Holding the end of the swab shaft, bend it at a 180 degrees angle to break at the marked breakpoint. If needed, gently twist the shaft between thumb and forefinger to completely remove it. Discard the broken upper part of the swab shaft and tighten the cap. Shake the vial until the sample appears homogeneous.
5) Write patient's name and demographics on the tube or apply a label and send the sample to the laboratory.
Test Limitations:
As with all PCR testing methods there is a risk of false positive or false negative values resulting from improperly collected, transported or handled specimens. A negative FilmArray RP2 result does not exclude the possibility of gastrointestinal infection. Negative test results may occur from the presence of sequence variants in the region targeted by the assay, the presence of inhibitors, technical error, sample mix-up or an infection caused by an organism not detected by the panel. Test results may also be affected by concurrent antibacterial therapy or levels of organism in the specimen that are below the limit of detection for the test. Negative results should not be used as the sole basis for diagnosis, treatment, or other patient management decisions. False negative results are more likely during peak activity when prevalence of disease is high. The risk of a false positive is more likely during periods when prevalence is moderate to low. A false positive can also occur due to cross-contamination by target organisms, their nucleic acids or amplified product. Erroneous results due to cross-reactivity with organisms that were not evaluated or new variant sequences that emerge is also possible. This test is not intended or evaluated for use on samples collected from patients who are immunocompromised.
Test Information:
Components:
Component Name | CPT | Loinc |
Adenovirus F 40/41 | 82209-8 | Astrovirus | 82210-6 | Campylobacter spp | 82196-7 | Clostridium difficile toxin A/B | 92197-5 | Cryptosporidium | 82205-6 | Cyclospora cayetanensis | 82206-4 | E. coli O157 | 82204-9 | Entamoeba histolytica | 82207-2 | Enteroaggregative E. Coli (EAEC) | 80349-4 | Enteropathogenic E. Coli (EPEC) | 80348-6 | Enterotoxigenic E.Coli (ETEC) lt/st | 80351-0 | Giardia lamblia | 82208-0 | Norovirus GI/GII | 82211-4 | Plesiomonas shigelloides | 82198-3 | Rotavirus A | 82212-2 | Salmonella | 82199-1 | Sapovirus | 82213-0 | Shiga-like-toxin-producing E.Coli (STEC) stx1/stx2 | 82203-1 | Shigella/Enteroinvasive E. Coli (EIEC) | 80350-2 | Vibrio cholerae | 82201-5 | Vibrio spp | 82200-7 | Yersinia enterocolitica | 82202-3 |